Comparative Expression of Breast Cancer 1 Tumor Suppressor Protein in Cancerous and Healthy Colorectal Specimens

Document Type : Original Article (s)

Authors

1 Associate Professor, Department of Anatomical Sciences, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Student of Medicine, School of Medicine AND Student Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Various tumor suppressor genes play a role in colorectal cancer; the role of breast cancer 1 (BRCA1) tumor suppressor gene is of the most importance among them. The biological performance of breast cancer 1 (BRCA1) in cancer has been recognized and its prognostic significance has been verified in colorectal cancer; decrease in the expression of this protein in cancer indicates a poor prognosis for patients. The aim of the current study was to evaluate BRCA1 protein expression in cancerous colorectal specimens compared to healthy tissue surrounding the tumor using immunohistochemistry method.Methods: A total of 50 cancerous colorectal and 50 healthy specimens were collected. The expression of BRCA1 protein was evaluated upon paraffin sections through immunohistochemistry method.Findings: The findings of the current study showed that the level of BRCA1 protein expression significantly decreased in cancerous specimens compared to healthy tissue surrounding the tumor (P = 0.026).Conclusion: The expression of BRCA1 could be used as an appropriate biological marker in the diagnosis and prognosis of colorectal cancer.

Keywords

References

  1. Thomas DS, Fourkala EO, Apostolidou S, Gunu R, Ryan A, Jacobs I, et al. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer 2015; 113(2): 268-74.
  2. Ling Y, Yang L, Huang H, Hu X, Zhao C, Huang H, et al. Prognostic significance of statin use in colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore) 2015; 94(25): e908.
  3. Pickhardt PJ. Colorectal carcinoma: what should the oncologist recommend for screening? Semin Oncol 2015; 42(3): 359-61.
  4. Dienstmann R, Salazar R, Tabernero J. Genomic testing in colorectal cancer: how much is enough? Oncology (Williston Park) 2015; 29(3): 186-8.
  5. Tang J, Xi S, Wang G, Wang B, Yan S, Wu Y, et al. Prognostic significance of BRCA1-associated protein 1 in colorectal cancer. Med Oncol 2013; 30(2): 541.
  6. Quann K, Jing Y, Rigoutsos I. Post-transcriptional regulation of BRCA1 through its coding sequence by the miR-15/107 group of miRNAs. Front Genet 2015; 6: 242.
  7. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol 2011; 29(16): 2247-52.
  8. Garg K, Levine DA, Olvera N, Dao F, Bisogna M, Secord AA, et al. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol 2013; 37(1): 138-46.
  9. Resnick K, Straughn JM, Jr., Backes F, Hampel H, Matthews KS, Cohn DE. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol 2009; 114(3): 530-6.
  10. Samadaian N, Modaresi MH, Mobasheri M, Ebrahim Zadeh Vesal R, Akrami SM. miRNA-21 expression analysis in 35 colorectal cancer. Tehran Univ Med J 2014; 72(5): 301-6. [In Persian].
  11. Davarnia B, Mehdipour P, Arei M, Hosseini-Asl SS. The association between BRCA1 expression and breast cancer tumorogenesis. J Ardabil Univ Med Sci 2012; 12(2): 132-9. [In Persian].
  12. Yuanming L, Lineng Z, Baorong S, Junjie P, Sanjun C. BRCA1 and ERCC1 mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer. BMC Cancer 2013; 13: 103.
  13. Grabsch H, Dattani M, Barker L, Maughan N, Maude K, Hansen O, et al. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res 2006; 12(5): 1494-500.
  14. Guanghui X, Yu L, Yi L. Relationship between BRCA1 expression and efficacy of platinum-based chemotherapy in colorectal cancer. J Transl Med 2014; 2(1): 240-4.
  15. Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, et al. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer 2014; 110(2): 530-4.
Journal of Isfahan Medical School
Volume 33, Issue 368 - Serial Number 368
November and December 2016
Pages 2455-2460

Files

History

  • Receive Date: 19 October 2015
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics